The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency
Open accessAbstract
OBJECTIVE: In HIV-infected individuals on antiretroviral therapy (ART), latent HIV is enriched in CD4 T cells expressing immune checkpoint molecules, in particular programmed cell death-1 (PD-1). We therefore assessed the effect of blocking PD-1 on latency, both in vitro and in vivo. METHODS: HIV latency was established in vitro following coculture of resting CD4+ T cells with myeloid dendritic cells. Expression of PD-1 was quantified by flow cytometry, and latency assessed in sorted PD-1high and PD-1low/-nonproliferating CD4+ memory T cells. The role of PD-1 in the establishment of latency was determined by adding anti-PD-1 (pembrolizumab) to cocultures before and after infection. In addition, a single infusion of anti-PD-1 (nivolumab) was administered to an HIV-infected individual on ART with metastatic melanoma, and cell-associated HIV DNA and RNA, and plasma HIV RNA were quantified. RESULTS: HIV latency was significantly enriched in PD-1high compared with PD-1low/- nonproliferating, CD4 memory T cells. Sorting for an additional immune checkpoint molecule, T-cell immunoglobulin domain and mucin domain-3, in combination with PD-1, further enriched for latency. Blocking PD-1 prior to HIV infection, in vitro, resulted in a modest but significant decrease in latently infected cells in all donors (n = 6). The administration of anti-PD-1 to an HIV-infected individual on ART resulted in a significant increase in cell-associated HIV RNA in CD4 T cells, without significant changes in HIV DNA or plasma HIV RNA, consistent with reversal of HIV latency. CONCLUSION: PD-1 contributes to the establishment and maintenance of HIV latency and should be explored as a target, in combination with other immune checkpoint molecules, to reverse latency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Fourth, the activity of anti-PD-1 (or anti-PD-L1) on latency reversal could potentially vary significantly in different recipients, as well described in responses to both antibodies for the management of malignancy [28].”
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“Given the successful clinical trials with concurrent administration of anti-CTLA-4 and antiPD-1 in individuals with malignancy [19,20], this is potentially feasible, although toxicity remains a significant concern with this combination [21].”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Given the successful clinical trials with concurrent administration of anti-CTLA-4 and antiPD-1 in individuals with malignancy [19,20], this is potentially feasible, although toxicity remains a significant concern with this combination [21].”
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
Chun, T.-W., Carruth, L., Finzi, D., Shen, X., DiGiuseppe, J. A., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Quinn, T. C., et al. (1997) · Nature · doi:10.1038/387183a0 · Cited by 2,050
Cited by
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lonberg, N. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 548
T‐cell exhaustion in HIV infection
Fenwick, C., Joo, V., Jacquier, P., Noto, A., Banga, R., Perreau, M., & Pantaleo, G. (2019) · Immunological Reviews · doi:10.1111/imr.12823 · Cited by 425
Yang, X., Su, B., Zhang, X., Liu, Y., Wu, H., & Zhang, T. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr1019-189r · Cited by 341
The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies
Cohn, L. B., Chomont, N., & Deeks, S. G. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.014 · Cited by 284
Self-citationAit-Ammar, A., Kula, A., Darcis, G., Verdikt, R., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Rohr, O., & Van Lint, C. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03060 · Cited by 163
Metadata
- Authors
- Evans, V. A., van der Sluis, R. M., Solomon, A., Dantanarayana, A., McNeil, C., Garsia, R., Palmer, S., Fromentin, R., Chomont, N., Sékaly, R.-P., Cameron, P. U., & Lewin, S. R.
- Venue
- AIDS
- Published
- 2018-07-17
- Volume
- 32
- Issue
- 11
- Pages
- 1491-1497
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2801428242
- Cited by
- 162
- References
- 5
- FWCI
- 11.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. https://app.cochat.ai/papers/10.1097/qad.0000000000001849
- The paper
- Evans, V. A., van der Sluis, R. M., Solomon, A., Dantanarayana, A., McNeil, C., Garsia, R., Palmer, S., Fromentin, R., Chomont, N., Sékaly, R.-P., Cameron, P. U., & Lewin, S. R. (2018). Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS. https://doi.org/10.1097/qad.0000000000001849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.